{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-002341","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.835307+00:00","generated_at":"2026-05-18T08:58:35.235904+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"SIL204 shows dose-dependent inhibition in KRAS G12D lung cancer cells in preclinical study","bullets":["Preclinical study demonstrates significant dose-dependent inhibition of human lung cancer cells with KRAS G12D mutation.","Company plans to release results of new study on previously untested KRAS mutation shortly; if positive, could support pan-KRAS potential.","SIL204's lipid-conjugated delivery system validated; overcoming a key barrier for siRNA in solid tumors.","Company continues to prepare for Phase 2/3 trial initiation in Q2 2026 for KRAS-driven solid tumors.","Builds on prior efficacy in pancreatic and colorectal cancer models; KRAS mutations occur in ~30% of lung cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-002341","json":"https://secwatch.observer/filing/0001178913-25-002341.json","markdown":"https://secwatch.observer/filing/0001178913-25-002341.md","text":"https://secwatch.observer/filing/0001178913-25-002341.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325002341/0001178913-25-002341-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325002341/zk2533417.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:58:35.235904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}